Table 1.
Characteristics of included studies
| Author | Year | Country | SD | Setting | Treatment | Sample size | Histologic diagnosis (n) | Gender (F/M) | Age at treatment (years) | Onset age (years) | Follow-up (months) | NS type (n) | eGFR (mL/min/1.73 m2) | Scr (mg/dL) | Albumin (g/dL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cortazar | 2019 | USA | R | S | RTX | 13 | MCD/FSGS 8/5 | 4/9 | 22–72 | NA | 35 (19–57) | SD/FR 12/1 | NA | 1.1 (0.8–1.3) | 2.7 (2.1–3.2) |
| Fenoglio | 2018 | Italy | R | S | RTX | 6 | MCD | 4/2 | 61 (59–72) | 45–73 | 8–36 | NA | NA | 0.8 (0.6–1.6) | 2.1 (1.7–2.3) |
| Iwabuchi | 2018 | Japan | R | S | RTX | 19 | MCD | 7/12 | 36.0 ± 11.4 | 30.6 ± 9.9 | 24 | NA | 85.2 ± 20.8 | 0.80 ± 0.20 | 3.60 ± 0.95 |
| Katsuno | 2018 | Japan | R | S | RTX | 8 | MCD | 5/3 | 43 (30–49.5) | 23 (22–41.5) | 13.9 (11.6–20) | SD 8 | 76.7 (68.2–87.8) | 0.69 (0.61–0.99) | 3.8 (3.3–4.0) |
| DaSilva | 2017 | Spain | R | M | RTX | 28 | MCD/FSGS 24/4 | 12/16 | 37 ± 15 | 25 ± 19 | 31 ± 26 | SD/FR 26/2 | 86 ± 21 | 0.84 ± 0.36 | 2.0 ± 0.5 |
| Steroid ± IS | 22 | MCD/FSGS 18/4 | 8/14 | NA | 27 ± 22 | 13 ± 8.3 (years) | SD/FR 20/2 | 89 ± 27 | 0.75 ± 0.19 | 1.9 ± 0.5 | |||||
| King | 2017 | UK | R | S | RTX | 13 | MCD | 3/10 | 23 (19–83) | 4 (1–80) | 20 (6–85) | SD/FR 10/13 | 90 | 0.75 (0.51–1.71) | 4.2 (3.1–5.2) |
| Ren | 2017 | China | P | S | RTX | 15 | MCD/FSGS 9/6 | 5/10 | 25 (16–54) | NA | 8 (3–36) | FR 15 | 128 (93–135) | 0.71 (0.48–0.88) | 3.7 (1.4–4.5) |
| Roccatello | 2017 | Italy | R | S | RTX | 8 | FSGS | 4/4 | 63.9 ± 14.0 | NA | 29.1 ± 8.8 | NA | NA | 2.6 ± 1.2 | 2.7 ± 0.15 |
| Brown | 2017 | USA | R | S | RTX | 5 | MCD | 0/5 | 57 (50–59) | NA | 39.5 (20–80) | SD 5 | NA | 0.98 (0.66–4.72) | 2.5 (1.9–4) |
| Papakrivopoulou | 2016 | UK | P | S | RTX | 15 | MCD | 6/9 | 27 (18–46) | 60% <18 years | 43 | SD/FR 8/7 | NA | 0.95 ± 0.24 | 4.14 ± 0.13 |
| Dekkers | 2015 | Netherlands | R | S | RTX | 10 | MCD | 2/8 | 26.4 ± 13.21 | 15.7 ± 14.4 | 43 ± 23.5 | NA | NA | NA | NA |
| Miyabe | 2015 | Japan | R | S | RTX | 54 | MCD | 13/41 | 28.2 ± 10.4 | NA | 24 | SD 54 | NA | 0.7 ± 0.02 | 3.7 ± 0.08 |
| Bruchfeld | 2014 | Sweden | R | S | RTX | 16 | MCD | 9/7 | 19–73 | 2–60 | 44 (12–70) | SD/FR 13/3 | NA | 0.92 (0.75–1.21) | 2.9–3.6 |
| Guitard | 2014 | France | P | M | RTX | 41 | MCD | 30/11 | 26 (15–83) | 6 (0.8–67) | 39 (6–71) | SD 8 | 93 ± 25 | 1.04 ± 0.29 | 3.2 ± 0.9 |
| Iwabuchi | 2014 | Japan | P | S | RTX | 25 | MCD | 4/21 | 30.1 ± 11.9 | NA | 24 | NA | NA | NA | 3.6 ± 0.8 |
| Ruggenenti | 2014 | Italy | P | M | RTX | 20 | MCD/FSGS 15/5 | 10/10 | 34.3 (22.7–47.4) | 20.6 (4.3–39.8) | 12 | SD/FR 15/5 | 105.0 ± 24.9 | 0.81 ± 0.19 | 3.86 ± 0.56 |
| Takei | 2013 | Japan | P | S | RTX | 25 | MCD | 6/19 | 30 ± 12 | NA | 12 | NA | NA | 0.7 ± 0.2 | 3.4 ± 0.8 |
| Munyentwali | 2013 | France | R | S | RTX | 17 | MCD | 4/13 | 29.4 (18.5–65) | 16 (1–63.2) | 29.5 (5.1–82.2) | SD 17 | 108 (61–175) | NA | 3.3 (2.2–3.8) |
| Kronbichler | 2013 | Austria | R | S | RTX | 5 | MCD/FSGS 2/3 | 1/4 | 29.4 ± 3.6 | 13.6 ± 8.4 | 22.6 ± 7.1 | SD 5 | NA | 0.93 ± 0.22 | 2.6 ± 0.9 |
| Kong | 2012 | Australia | R | S | RTX | 11 | MCD/FSGS 7/4 | 6/5 | 19 (13–44) | NA | 31.5 (15–44) | NA | NA | NA | NA |
| Hoxha | 2011 | Germany | P | S | RTX | 6 | MCD | 1/5 | 24.8 ± 6.3 | NA | 17.2 ± 4.8 | SD/FR | NA | 0.5–1.2 | NA |
SD, study design; M, male; F, female; R, retrospective; P, prospective; S, single center; M, multicenter; n, number; NA, not available; IS, immunosuppression.